Hearing loss after exposure to vincristine and platinum-based chemotherapy among childhood cancer survivors | Strebel et al.

## Supplementary data

**SUPPLEMENTARY TABLE A.1** Sensitivity analysis including CNS tumor diagnosis into the regression analysis


	SIOP-Boston grade $\leq 1$ n=172		SIOP-Boston grade ≥ 2 n=98		Univariable		Multivariable <sup>a</sup>	
	n	(%)	n	(%)	OR <sup>b</sup> (95%-CI)	<i>P</i> -value <sup>c</sup>	ORb (95%-CI)	<i>P</i> -value <sup>c</sup>
Sex						0.778		0.728
Female	75	(44)	41	(42)	Reference		Reference	
Male	97	(56)	57	(58)	1.1 (0.7-1.8)		1.1 (0.6-2.2)	
Age at audiogram						0.006		< 0.001
< 10 years	63	(37)	18	(18)	Reference		Reference	
10-15 years	62	(36)	46	(47)	2.6 (1.4-5.0)		8.0 (2.7-23.3)	
> 15 years	47	(27)	34	(35)	2.5 (1.3-5.0)		8.0 (2.3-27.6)	
Age at cancer diagnosis						0.001		< 0.001
< 5 years	61	(35)	51	(52)	3.0 (1.6-5.5)		9.0 (3.0-27.1)	
5-9 years	40	(23)	27	(28)	2.4 (1.2-4.8)		2.4 (0.9-6.1)	
10-18 years	71	(41)	20	(20)	Reference		Reference	
Period of cancer diagnosis						< 0.001		0.011
1990-1995	18	(10)	30	(31)	7.4 (3.1-17.3)		5.4 (1.8-16.1)	
1996-2001	46	(27)	29	(30)	2.8 (1.3-6.1)		1.7 (0.6-4.7)	
2002-2007	55	(32)	27	(28)	2.2 (1.0-4.7)		1.4 (0.6-3.7)	
2008-2014	53	(31)	12	(12)	Reference		Reference	
CNS tumor diagnosis						0.004		0.711
No	117	(68)	49	(50)	Reference		Reference	
Yes	55	(32)	49	(50)	2.1 (1.3-3.5)		0.8 (0.2-2.7)	
Treatments								
Platinum-based chemotherapy						< 0.001		< 0.001
Carboplatin only	54	(31)	8	(8)	Reference		Reference	
Cisplatin only	94	(55)	57	(58)	4.1 (1.8-9.2)		15.7 (5.1-48.3)	
Both platinum agents	24	(14)	33	(34)	9.3 (3.7-23.1)		9.2 (2.8-30.0)	
Vincristine						< 0.001		0.004
No	98	(57)	27	(28)	Reference		Reference	
Yes	74	(43)	71	(72)	3.5 (2.0-6.0)		5.3 (1.7-17.0)	
Cranial radiation						0.001		0.265
No	122	(71)	50	(51)	Reference		Reference	
Yes	50	(29)	48	(49)	2.3 (1.4-3.9)		1.9 (0.6-5.6)	
HSCT						< 0.001		0.021
No	166	(97)	78	(80)	Reference		Reference	
Yes	6	(3)	20	(20)	7.1 (2.7-18.4)		4.9 (1.3-19.0)	

Abbreviations: CI, confidence interval; CNS, central nervous system; HSCT, hematopoietic stem cell transplantation, OR, odds ratio; SIOP, International Society of Pediatric Oncology.

<sup>&</sup>lt;sup>a</sup>Factors associated with hearing loss at *P* < 0.05 were included in the multivariable analyses. Sex, age at audiogram, and age at cancer diagnosis were included in the multivariable model independent of the strength of the association in the respective univariable model.

bOdds ratio from univariable and multivariable logistic regression models: OR < 1 indicates that SIOP-Boston grade ≤1 is more likely. OR > 1 indicates that SIOP-Boston grade ≥ 2 is more likely.

<sup>c</sup>Global *P*-value calculated from likelihood-ratio test.



**SUPPLEMENTARY FIGURE A.1** Distribution of the calculated total cumulative vincristine dose overall [A] and stratified by hearing function [B] (n=140, excluding 5 survivors with missing dose information).